Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019) Pavel ME, Broberg P, Caplin M, Ruszniewski P, Strosberg J, Santoro P, Ravasi L, Krenning E Conference contribution Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019) Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al. Conference contribution Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019) Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article